The Liver Meeting 2024 - Debrief Sessions - Portuguese-MASLD Debrief Session

Video Transcription

Video Summary

Dr. Alina Allen from the Mayo Clinic highlighted significant advances in Masold research during a recent presentation. The 2024 focus included omics, pediatric data, and drug therapies, particularly genomics studies on resmeterome’s effects and the role of genetic risk markers in treatments such as terzapatide. The study showed terzapatide had a greater effect on certain genotypes, indicating the need for more research. Proteomics and metabolomics studies offered insights into differentiating Masold from metALD, especially in pediatric patients. The impact of GLP-1 receptor agonists on Masold, notably in pediatric cases, was discussed, showing potential improvements despite no weight loss. Clinical trial advancements included promising results from drugs like efruxifermin and semaglutide in improving liver fibrosis and achieving Masold treatment goals. The session concluded with an emphasis on how genetic factors might predict treatment response, highlighting the importance of continued research in developing targeted Masold therapies.

Keywords

Masold research

genomics studies

pediatric data

terzapatide

proteomics

GLP-1 receptor agonists